These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 28106152)

  • 1. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
    Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
    Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
    Iglesias P
    Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
    González-Rodríguez E; Rodríguez-Abreu D;
    Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
    Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
    Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine side effects of cancer immunotherapy.
    Cukier P; Santini FC; Scaranti M; Hoff AO
    Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
    Iwama S; Arima H
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune-related adverse events of immune checkpoint inhibitors].
    Tadano H; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to dissect the autoimmune etiology of cancer antibody immunotherapy.
    Dougan M; Pietropaolo M
    J Clin Invest; 2020 Jan; 130(1):51-61. PubMed ID: 31895048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.